FDA Approves Ilumya for Psoriatic Arthritis

The FDA has approved Ilumya, also known as tildrakizumab-asmn, for the treatment of psoriatic arthritis, according to Techtimes. The approval occurred on October 30, 2026.

Techtimes identifies Ilumya as a Sun Pharma IL-23 inhibitor. The authorization adds a new treatment option in psoriatic arthritis and establishes a notable administration distinction within its reported drug class.

Office-administered IL-23 inhibitor

According to Techtimes, Ilumya is the only biologic in its class that requires in-office administration for every dose. That administration model differentiates the product from self-injectable IL-23 inhibitor rivals named by the publisher.

Techtimes specifically contrasts Ilumya with guselkumab and risankizumab, which it characterizes as self-injectable alternatives. The difference places healthcare-office administration at the center of the product’s positioning following the FDA decision.

Commercial relevance for pharmaceutical sales teams

For pharmaceutical sales professionals focused on immunology and rheumatology accounts, the reported approval creates a new FDA-authorized Ilumya indication to discuss with relevant clinical stakeholders. The in-office requirement cited by Techtimes may be particularly relevant in conversations about how treatment is administered across the care setting.

The approval also provides a clear point of comparison with guselkumab and risankizumab: Techtimes reports that those rivals are self-injectable, while every Ilumya dose is administered in an office. Sales conversations can therefore center on the approved psoriatic arthritis use and the administration distinction described by the publisher.

What was announced

• The FDA approved Ilumya for psoriatic arthritis treatment on October 30, 2026, according to Techtimes.
• Ilumya is tildrakizumab-asmn and is identified by Techtimes as a Sun Pharma IL-23 inhibitor.
• Techtimes reports that every Ilumya dose requires in-office administration.
• The publisher identifies guselkumab and risankizumab as self-injectable rivals.